On the evening of April 14, Polaris Pharmaceuticals-KY announced that it had signed commercialization and distribution agreements with two international companies—Tabuk Pharmaceutical Manufacturing Company and Er-Kim Pharmaceuticals—for its novel anticancer metabolic therapy, ADI-PEG 20.
Polaris stated that the agreement with Tabuk Pharmaceutical Manufacturing Company will take effect on April 14, 2025, and will remain valid for six years. Under the agreement, Polaris grants Tabuk exclusive commercial rights to market ADI-PEG 20 for the treatment of malignant pleural mesothelioma (MPM) in Saudi Arabia and seven countries in the Gulf Cooperation Council (GCC) region. Product shipments will commence once Polaris assists Tabuk in completing the necessary regulatory reviews and obtaining marketing authorization in the licensed territories.
According to Polaris, Tabuk is a wholly owned subsidiary of the publicly listed Astra Industrial Group in Saudi Arabia. Founded in 1994, Tabuk is a leading pharmaceutical company in the Kingdom, with business operations spanning the Middle East and North Africa (MENA) region. The company develops, manufactures, markets, and distributes a wide range of branded and generic medicines. It also produces pharmaceutical products for its international partners at its manufacturing facility in Saudi Arabia. Tabuk currently serves patients in 17 countries and territories across the MENA region and plans to further expand its presence in the area.
In addition, the agreement with Er-Kim Pharmaceuticals also takes effect on April 14, 2025, and will last for eight years. Under this agreement, Polaris grants Er-Kim exclusive distribution rights for ADI-PEG 20 in 36 markets within the EMEA region—which includes Central and Eastern Europe, Eurasia, North Africa, and the Mediterranean—for the treatment of malignant pleural mesothelioma (MPM). Er-Kim will be responsible for the sales of ADI-PEG 20 in the licensed markets.
Founded in 1981, Er-Kim stands at the forefront of innovation in biopharmaceuticals. The company collaborates with over 40 leading global enterprises and operates as a full-service solutions provider. Through its wholly owned subsidiaries, Er-Kim extends its reach to over 600 million patients. It employs a team of more than 280 professionals worldwide and generates annual revenues exceeding €260 million.
Resource: 北極星藥業與兩國際公司簽商業化及通路銷售合作合約
